Mitogen-activated protein kinase kinase
(Redirected from MAPKK)
| Mitogen-activated protein kinase kinase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC no. | 2.7.12.2 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| |||||||||
Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a dual-specificity kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).
MAP2K is classified as EC 2.7.12.2.
There are seven genes:
- MAP2K1 (a.k.a. MEK1)
- MAP2K2 (a.k.a. MEK2)
- MAP2K3 (a.k.a. MKK3)
- MAP2K4 (a.k.a. MKK4)
- MAP2K5 (a.k.a. MKK5)
- MAP2K6 (a.k.a. MKK6)
- MAP2K7 (a.k.a. MKK7)
The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.[1] The acronym MEK derives from MAPK/ERK Kinase.[2]
Role in melanoma
[edit]MEK is a member of the MAPK signaling cascade that is activated in melanoma.[3] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.
See also
[edit]References
[edit]- ^ Dérijard B, et al. (1995). "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms". Science. 267 (5198): 682–5. Bibcode:1995Sci...267..682D. doi:10.1126/science.7839144. PMID 7839144. S2CID 9153074.
- ^ Dwivedi, Gaurav; Kemp, Melissa L. (February 15, 2012). "Systemic Redox Regulation of Cellular Information Processing". Antioxidants & Redox Signaling. 16 (4): 374–80. doi:10.1089/ars.2011.4034. PMC 3279717. PMID 21939387.
- ^ Falchook, Gerald S.; Lewis, Karl D.; Infante, Jeffrey R.; Gordon, Michael S.; Vogelzang, Nicholas J.; DeMarini, Douglas J.; Fecher, Leslie A.; et al. (2012). "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial". The Lancet Oncology. 13 (8): 782–789. doi:10.1016/S1470-2045(12)70269-3. PMC 4109286. PMID 22805292.
External links
[edit]- Mitogen-Activated+Protein+Kinase+Kinases at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
 | This protein-related article is a stub. You can help Wikipedia by expanding it. |